Cardinal Health (NYSE:CAH) reported first quarter fiscal year 2027 results on November 5, 2026, disclosing revenue of $67.5 billion, raised non-GAAP EPS guidance to $12.80 to $13.00, and announced the completion of a $500 million share repurchase program.

Key Highlights

  • Revenue up 5%: First quarter revenue reached $67.5 billion, compared to $64.0 billion in Q1 FY26.
  • GAAP diluted EPS of $2.38: A 27% increase from $1.88 in the prior-year quarter.
  • Non-GAAP diluted EPS of $3.26: A 28% increase from $2.55 in Q1 FY26, reflecting higher non-GAAP operating earnings, a lower share count, and a lower effective tax rate.
  • Guidance raised: Fiscal year 2027 non-GAAP diluted EPS guidance increased to $12.80 to $13.00, up from the previous range of $12.40 to $12.60.
  • Share repurchase completed: The company completed its $500 million accelerated share repurchase program in the first quarter.
  • Pharmaceutical and Specialty Solutions segment profit up 17%: Segment profit rose to $783 million from $667 million in Q1 FY26.
  • Global Medical Products and Distribution segment profit declined: Segment profit fell 28% to $33 million, from $46 million in Q1 FY26.

Cardinal Health First Quarter FY27 Segment and Guidance Details

According to the filing, Cardinal Health's Pharmaceutical and Specialty Solutions segment drove the bulk of consolidated revenue, with first quarter revenue increasing 6% to $62.6 billion. The company attributed this growth to brand and specialty pharmaceutical sales growth from existing customers. Segment profit for this division rose 17% to $783 million, primarily driven by contributions from brand and specialty products and positive generics program performance.

The Global Medical Products and Distribution (GMPD) segment reported revenue of approximately $3.2 billion, described as "approximately flat to the prior year," with growth in Cardinal Health Brand offset by lower distribution revenue. GMPD segment profit declined to $33 million from $46 million, due to what the filing described as unfavorable distribution and foreign exchange impacts, partially offset by Cardinal Health Brand growth. The segment reported as "Other" - comprising Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics - posted revenue of $1.8 billion, a 7% increase, and profit of $193 million, a 16% increase.

The updated fiscal year 2027 non-GAAP EPS guidance of $12.80 to $13.00 reflects, according to the filing, raised Pharmaceutical and Specialty Solutions profit growth guidance to 10% to 12% (from 8% to 11%), raised Other profit growth to 17% to 20% (from 15% to 18%), a lowered non-GAAP effective tax rate assumption of 18.5% to 19.5% (from 19.0% to 20.0%), and diluted weighted average shares outstanding of 231 million to 232 million. The filing also noted that Cardinal Health entered into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health, and anticipates completing the acquisition of AdaptHealth's Diabetes Health business in Q3 of fiscal 2027.

What Was Disclosed

Cardinal Health disclosed its Q1 fiscal year 2027 earnings results, including revenue of $67.5 billion, GAAP diluted EPS of $2.38, non-GAAP diluted EPS of $3.26, raised full-year non-GAAP EPS guidance to $12.80 to $13.00, and completion of a $500 million share repurchase program.